Home The Word Brain My Amedeo FAQ Privacy About   

As of October 2023, Amedeo had
12,263 active subscribers

  Lung Cancer

  Free Subscription

Articles published in Am J Pathol

Retrieve available abstracts of 13 articles:
HTML format

Single Articles

    December 2023
  1. LAMI K, Ota N, Yamaoka S, Bychkov A, et al
    Standardized Classification of Lung Adenocarcinoma Subtypes and Improvement of Grading Assessment Through Deep Learning.
    Am J Pathol. 2023;193:2066-2079.
    PubMed     Abstract available

    October 2023
  2. ZHU D, Nie Y, Zhao Y, Chen X, et al
    RNF152 Suppresses Fatty Acid Oxidation and Metastasis of Lung Adenocarcinoma by Inhibiting IRAK1-Mediated AKR1B10 Expression.
    Am J Pathol. 2023;193:1603-1617.
    PubMed     Abstract available

    May 2023
  3. PENG M, Hu Q, Wu Z, Wang B, et al
    Mutation of TP53 confers ferroptosis resistance in lung cancer through the FOXM1/MEF2C axis.
    Am J Pathol. 2023 May 24:S0002-9440(23)00173.
    PubMed     Abstract available

    January 2023
  4. ZHANG H, Qureshi MA, Wahid M, Charifa A, et al
    Differential Diagnosis of Hematologic and Solid Tumors Using Targeted Transcriptome and Artificial Intelligence.
    Am J Pathol. 2023;193:51-59.
    PubMed     Abstract available

    October 2022
  5. ZHAI WY, Duan FF, Wang YZ, Wang JY, et al
    Integrative Analysis of Bioinformatics and Machine Learning Algorithms Identifies a Novel Diagnostic Model Based on Costimulatory Molecule for Predicting Immune Microenvironment Status in Lung Adenocarcinoma.
    Am J Pathol. 2022;192:1433-1447.
    PubMed     Abstract available

    August 2022
  6. KANTARCI A, Kansal S, Hasturk H, Stephens D, et al
    Resolvin E1 Reduces Tumor Growth in a Xenograft Model of Lung Cancer.
    Am J Pathol. 2022 Aug 6. pii: S0002-9440(22)00215.
    PubMed     Abstract available

    June 2022
  7. MASAWA M, Sato-Yazawa H, Kashiwagi K, Ishii J, et al
    REST Inactivation and Coexpression of ASCL1 and POU3F4 Are Necessary for the Complete Transformation of RB1/TP53-Inactivated Lung Adenocarcinoma into Neuroendocrine Carcinoma.
    Am J Pathol. 2022;192:847-861.
    PubMed     Abstract available

  8. ZHOU Y, Chang M, Wang N, Zhuang Y, et al
    Phosphatidylserine-Specific Phospholipase A1 Limits Aggressiveness of Lung Adenocarcinoma by Lysophosphatidylserine and Protein Kinase A-Dependent Pathway.
    Am J Pathol. 2022;192:970-983.
    PubMed     Abstract available

    April 2022
  9. PARK J, Cho HG, Park J, Lee G, et al
    Artificial Intelligence-Powered Hematoxylin and Eosin Analyzer Reveals Distinct Immunologic and Mutational Profiles among Immune Phenotypes in Non-Small-Cell Lung Cancer.
    Am J Pathol. 2022;192:701-711.
    PubMed     Abstract available

    December 2021
  10. DEHKHARGHANIAN T, Rahnamayan S, Riasatian A, Bidgoli AA, et al
    Selection, Visualization, and Interpretation of Deep Features in Lung Adenocarcinoma and Squamous Cell Carcinoma.
    Am J Pathol. 2021;191:2172-2183.
    PubMed     Abstract available

    November 2021
  11. KHADIRNAIKAR S, Chatterjee A, Shukla S
    Identification and Characterization of Senescence Phenotype in Lung Adenocarcinoma with High Drug Sensitivity.
    Am J Pathol. 2021;191:1966-1973.
    PubMed     Abstract available

    September 2021
  12. WANG Y, Yan F, Nasar A, Chen ZS, et al
    CUL4(high) Lung Adenocarcinomas Are Dependent on the CUL4-p21 Ubiquitin Signaling for Proliferation and Survival.
    Am J Pathol. 2021;191:1638-1650.
    PubMed     Abstract available

    July 2021
  13. GOERTZEN N, Pappesch R, Fassunke J, Bruning T, et al
    Quantum Cascade Laser-Based Infrared Imaging as a Label-Free and Automated Approach to Determine Mutations in Lung Adenocarcinoma.
    Am J Pathol. 2021;191:1269-1280.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.